CCR6 and COVID-19: Finally, we found that CM and EM Tc17.1 (CCR6+CXCR3+) were dramatically decreased in patients with acute COVID-19 compared to COVID-19 convalescents and healthy controls (4.88% (3.73; 7.25) vs. 10.52% (6.64; 13.12), p < 0.001 and 11.09% (5.80; 16.87), p < 0.001 and 5.69% (3.23; 10.77) vs. 18.47% (11.92; 28.95), p < 0.001 and 23.53% (9.94; 33.59), p < 0.001) (Figure 7M–P).